½ÃÀ庸°í¼­
»óǰÄÚµå
1602767

¼¼°èÀÇ µ¿¹° ¹é½Å ½ÃÀå : Á¦Ç° À¯Çüº° ¿¹Ãø(2025-2030³â)

Animal Vaccines Market by Product (Attenuated Live Vaccines, DNA Vaccines, Inactivated Vaccines), Animal Type (Aqua, Companion, Poultry) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

µ¿¹° ¹é½Å ½ÃÀåÀº 2023³â¿¡ 163¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 177¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.34%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 287¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µ¿¹° ¹é½Å ½ÃÀåÀº °¡Ãà, °¡Ãà, ¾ß»ýµ¿¹°ÀÇ Áúº´À» ¿¹¹æÇϰí ÅëÁ¦Çϱâ À§ÇØ °³¹ßµÈ ´Ù¾çÇÑ ¸é¿ªÇÐÀû Á¦Ç°À» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ¹é½ÅÀº µ¿¹°ÀÇ °Ç°­À» º¸È£ÇÏ°í ³ó¾÷ »ý»ê¼ºÀ» Çâ»ó½Ã۰í Àΰ£ Áü½Â °øÅë °¨¿°ÀÇ Àΰ£À¸·ÎÀÇ Àü´ÞÀ» °¨¼Ò½ÃŰ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ±× ¿ëµµ´Â ¹Ý·Áµ¿¹°¿¡ ´ëÇÑ Á¤±âÀûÀÎ ¿¹¹æ Á¢Á¾ºÎÅÍ ¼Ò, °¡±Ý·ù, µÅÁö µî °¡Ãà¿¡ ´ëÇÑ ´ë±Ô¸ð Á¢Á¾¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù. ƯÁ¤ ÃÖÁ¾ »ç¿ëÀÚ´Â µ¿¹° º´¿ø, Ŭ¸®´Ð, ³óÀå, ¿¬±¸ ±â°ü µîÀÔ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ´Â °ÍÀº ¹Ý·Áµ¿¹°ÀÇ »çÀ°¼ö Áõ°¡, µ¿¹° À¯·¡ÀÇ ½ÄǰÀÇ ¼Òºñ·® Áõ°¡, µ¿¹°ÀÇ °Ç°­¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡ÀÔ´Ï´Ù. °Ô´Ù°¡, Àηù °øÅë °¨¿°ÀÇ ¹ß»ý¿¡ ´ëÇÑ ¼¼°è ¿ì·Á Áõ°¡´Â ¾ö°ÝÇÑ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ Á߿伺À» µ¸º¸ÀÌ°Ô ÇÕ´Ï´Ù. ÀçÁ¶ÇÕ DNA ¹é½Å ¹× ³ª³ëÀÔÀÚ ±â¹Ý Àü´Þ ½Ã½ºÅÛ°ú °°Àº ±â¼úÀû Áøº¸´Â ±â¼ú Çõ½ÅÀÇ Å« ±âȸ¸¦ °¡Á®¿É´Ï´Ù. ±â¾÷Àº ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Áøº¸¸¦ Ȱ¿ëÇÏ¿© ÀûÀº ¿ë·®À¸·Î º¸´Ù ³ÐÀº ¿¹¹æÈ¿°ú¸¦ Á¦°øÇÏ´Â ¹é½ÅÀ» °³¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀå °³Ã´Àº ¾ö°ÝÇÑ ±ÔÁ¦ üÁ¦, ³ôÀº °³¹ß ºñ¿ë, ½ÅÈï ±¹°¡¿¡¼­ ¹é½Å º¸°ü ¹× À¯Åë ¹®Á¦¿Í °°Àº ¿©·¯ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Á¤ºÎ±â°ü°ú Á¦ÈÞÇÏ°í ½ÂÀÎ ÇÁ·Î¼¼½º¸¦ ÇÕ¸®È­Çϱâ À§ÇØ AI ÁÖµµÀÇ ºÐ¼®À» Ȱ¿ëÇÔÀ¸·Î½á ÀÌ·¯ÇÑ À庮¿¡ ´ëóÇÔÀ¸·Î½á ½ÃÀå ħÅõ¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶Ç, º¹¼öÀÇ º´¿øÃ¼¿¡ ´ëÇÑ ±³Â÷ ¹æ¾î¸¦ Á¦°øÇÏ´Â ¹é½ÅÀÇ °³¹ß, ÄÄÇöóÀÌ¾ð½º¿Í Åõ¿© ¿ëÀ̼ºÀ» °³¼±Çϱâ À§ÇÑ °æ±¸¡¤ºñ°­ Åõ¿©¹ýÀÇ Å½±¸¿¡µµ ±âȸ°¡ ÀÖ½À´Ï´Ù.°³º°È­ ¼öÀÇÇÐ ÀÇ·á ¹× µ¥ÀÌÅÍ ºÐ¼®¿¡ ÁÖ·ÂÇÔÀ¸·Î½á Áö¿ª Áúº´ À¯Çà°ú µ¿¹° Àα¸ Åë°è¸¦ ¹ÙÅÁÀ¸·Î ¸ÂÃãÇü ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥À» Á¦°øÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ À§ÇØ ±â¾÷Àº Çõ½Å, Àü·«Àû Á¦ÈÞ, ½ÅÈï ½ÃÀå ÁøÃâÀ» ¿ì¼±½ÃÇÏ°í ¹é½Å Á¢Á¾ÀÇ ÀÌÁ¡¿¡ ´ëÇØ ÇÏ´Â ÀνÄÀ» ³ôÀ̱â À§ÇÑ ±³À°Àû ´ëóµµ ½Ç½ÃÇØ¾ß ÇÕ´Ï´Ù. ±Ø´ëÈ­Çϱâ À§Çؼ­´Â ´Ù¾çÇÑ ±ÔÁ¦¿Í ¹°·ù Àå¾Ö¹°À» ±Øº¹ÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ (2023³â) 163¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 177¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 287¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 8.34%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â µ¿¹° ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

µ¿¹° ¹é½Å ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¶ÇÇÑ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °¡Ãà Àα¸ Áõ°¡
    • Ãà»ê¹°ÀÇ »ó¾÷È­¿¡ ¼ö¹ÝÇÏ´Â Ãà»ê Áõ°¡
    • Àμö °øÅë °¨¿°Áõ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °ø±Þºñ¿ëÀº ºñ±³Àû ³ô°í, ÀÚº»¼öÀÍ·üÀº Àΰ£¿ë ¹é½Åº¸´Ù ³·´Ù
  • ½ÃÀå ±âȸ
    • »ý¹é½Å¿¡¼­ DNA ¹é½ÅÀ¸·ÎÀÇ À̵¿
    • ¹é½ÅÀÇ Áö¼ÓÀûÀÎ ±â¼ú Áøº¸
  • ½ÃÀåÀÇ °úÁ¦
    • ¹é½ÅÀÇ ¾Ç¿µÇâ

Porter's Five Force : µ¿¹° ¹é½Å ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : µ¿¹° ¹é½Å ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº µ¿¹° ¹é½Å ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹ÃøÇÒ ¼ö ÀÖ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ µÇ¾ú½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : µ¿¹° ¹é½Å ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

µ¿¹° ¹é½Å ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ºÐ¸íÈ÷ ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁß, ºÎ¹®È­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í, º¥´õ´Â °æÀïÀÌ °ÝÈ­µÇ´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Âµ¥ ÇÊ¿äÇÑ Áö°ßÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : µ¿¹° ¹é½Å ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â µ¿¹° ¹é½Å ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : µ¿¹° ¹é½Å ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

µ¿¹° ¹é½Å ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ¸¶·ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ ´Ù·ç´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®¿¡¼­ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ¼³¸íÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° ½ÃÀå, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾òÀº ÈÄ ÀÇ»ç°áÁ¤ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡µµ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • °¡Ãà Áõ°¡
      • Ãà»ê¾÷ÀÇ ¹ßÀü°ú Ãà»ê¹°ÀÇ »ó¾÷È­
      • Àμö °øÅë °¨¿°ÁõÀÇ ¹ß»ý·ü Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • °ø±Þºñ¿ëÀº ºñ±³Àû ³ô°í, Àΰ£¿ë ¹é½Åº¸´Ù ÀÚº»¼öÀÍ·üÀÌ ³·´Ù
    • ±âȸ
      • »ý¾àµ¶È­ ¹é½Å¿¡¼­ DNA ¹é½ÅÀ¸·ÎÀÇ Àüȯ
      • ¹é½ÅÀÇ Áö¼ÓÀûÀÎ ±â¼ú Áøº¸
    • °úÁ¦
      • ¹é½ÅÀÇ ºÎÀÛ¿ë
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå µ¿¹° ¹é½Å ½ÃÀå : Á¦Ç°º°

  • ¼Ò°³
  • ¾àµ¶»ý ¹é½Å
  • DNA ¹é½Å
  • ºÒȰ¼ºÈ­ ¹é½Å
  • ÀçÁ¶ÇÕ ¹é½Å
  • ¼­ºê À¯´Ö ¹é½Å

Á¦7Àå µ¿¹° ¹é½Å ½ÃÀå : µ¿¹° À¯Çüº°

  • ¼Ò°³
  • ¼ö»ýµ¿¹°
    • ¿¡·Î¸ð³ª½º
    • ¿¬¼â»ó ±¸±ÕÁõ
    • ºñºê¸®¿À
  • ¹Ý·Áµ¿¹°
    • °³
      • °³ Ç츣Æä½º
      • µð½ºÅÛÆÛ
      • Ä˳ÚÄÚÇÁ
      • ¶óÀÓº´
      • ÆÄ¸£º¸¹ÙÀÌ·¯½º
      • ±¤°ßº´°ß
    • °í¾çÀÌ
      • Ä®¸®½Ã¹ÙÀÌ·¯½º
      • Äڷγª ¹ÙÀÌ·¯½º °í¾çÀÌ
      • ¹ü¹éÇ÷±¸°¨¼ÒÁõ
      • ±¤°ßº´ °í¾çÀÌ
      • ºñ±â°ü¿°
  • °¡±Ý
    • Á¶·ù ÀÎÇ÷翣ÀÚ
    • °¨¿°¼º ±â°üÁö¿°
    • ¸»·ºº´
    • ´ºÄ³½½º´
    • »ì¸ð³Ú¶ó
  • ¹ÝÃßµ¿¹°
    • Äڷγª¹ÙÀÌ·¯½º ¹ÝÃßµ¿¹°
    • ´ëÀå±Õ
    • ±¸Á¦¿ª(FMD)
    • ·¥ÇǽºÅ²º´
    • ·ÎŸ¹ÙÀÌ·¯½º

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ µ¿¹° ¹é½Å ½ÃÀå

  • ¼Ò°³
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾ç µ¿¹° ¹é½Å ½ÃÀå

  • ¼Ò°³
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µ¿¹° ¹é½Å ½ÃÀå

  • ¼Ò°³
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Anicon Labor GmbH by SAN Group
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private limited
  • Ceva Sante Animale
  • China Animal Husbandry Industry Co., Ltd.
  • Dalan Animal Health.
  • Eli Lilly and Company
  • Endovac Animal Health, LLC
  • Heska Corporation
  • Hester Biosciences Limited
  • HIPRA, SA
  • Indian Immunologicals Limited
  • Merck KGaA
  • Neogen Corporation
  • Pfizer Inc.
  • Phibro Animal Health Corporation
  • Sanofi SA
  • Torigen Pharmaceuticals Inc.
  • Vaxxinova GmbH
  • VEROVACCiNES GmbH
  • Vetigenics
  • Vetoquinol SA
  • Virbac, Inc.
  • Zoetis Inc.
JHS 24.12.12

The Animal Vaccines Market was valued at USD 16.39 billion in 2023, expected to reach USD 17.75 billion in 2024, and is projected to grow at a CAGR of 8.34%, to USD 28.72 billion by 2030.

The animal vaccines market encompasses various immunological products developed to prevent and control diseases in domesticated animals, livestock, and wildlife. These vaccines are crucial for safeguarding animal health, improving agricultural productivity, and reducing the transmission of zoonotic diseases to humans. Their applications range from routine immunizations in pets to large-scale inoculations in livestock like cattle, poultry, and pigs, with specific end-users comprising veterinary hospitals, clinics, farms, and research institutions. Market growth is fueled by rising pet ownership, increased consumption of animal-derived food products, and heightened awareness of animal health. Moreover, growing global concerns about zoonotic disease outbreaks have highlighted the significance of rigorous vaccination programs. Technological advancements, such as recombinant DNA vaccines and nanoparticle-based delivery systems, present vast opportunities for innovation. Companies can leverage these advancements by investing in R&D to develop vaccines offering broader protection with fewer doses. However, market expansion faces several challenges, including stringent regulatory frameworks, high development costs, and vaccine storage and distribution issues in developing regions. Addressing these barriers by partnering with government agencies and harnessing AI-driven analytics for streamlined approval processes can enhance market penetration. Opportunities also lie in developing vaccines that provide cross-protection against multiple pathogens, as well as exploring oral and intranasal delivery methods to improve compliance and ease of administration. Focusing on personalized veterinary medicine and data analytics can provide tailored vaccination programs based on regional disease prevalence and animal demographics, fostering market growth. To remain competitive, companies should prioritize technological innovation, strategic alliances, and expansion into emerging markets, coupled with educational initiatives to raise awareness about the benefits of vaccination. In summary, the animal vaccines market is poised for sustained growth, driven by technological advancements and a growing emphasis on animal health, though it must navigate various regulatory and logistical hurdles to maximize potential.

KEY MARKET STATISTICS
Base Year [2023] USD 16.39 billion
Estimated Year [2024] USD 17.75 billion
Forecast Year [2030] USD 28.72 billion
CAGR (%) 8.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Animal Vaccines Market

The Animal Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Livestock Population
    • Rising Animal Husbandry along with Commercialization of Animal Products
    • Increasing Incidences of Zoonotic Diseases
  • Market Restraints
    • Supply End Costs are Relatively High, with Poorer Capital Returns than Human Vaccines
  • Market Opportunities
    • Shift from Live Attenuated Vaccines to DNA Vaccines
    • Continuous Technological Advancements in Vaccines
  • Market Challenges
    • Adverse Impacts of Vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Animal Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Animal Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Animal Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Animal Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Animal Vaccines Market

A detailed market share analysis in the Animal Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Animal Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Animal Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Animal Vaccines Market

A strategic analysis of the Animal Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Animal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Anicon Labor GmbH by SAN Group, Biogenesis Bago S.A., Boehringer Ingelheim International GmbH, Brilliant Bio Pharma Private limited, Ceva Sante Animale, China Animal Husbandry Industry Co., Ltd., Dalan Animal Health., Eli Lilly and Company, Endovac Animal Health, LLC, Heska Corporation, Hester Biosciences Limited, HIPRA, S.A., Indian Immunologicals Limited, Merck KGaA, Neogen Corporation, Pfizer Inc., Phibro Animal Health Corporation, Sanofi S.A., Torigen Pharmaceuticals Inc., Vaxxinova GmbH, VEROVACCiNES GmbH, Vetigenics, Vetoquinol SA, Virbac, Inc., and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Animal Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Attenuated Live Vaccines, DNA Vaccines, Inactivated Vaccines, Recombinant Vaccines, and Subunit Vaccines.
  • Based on Animal Type, market is studied across Aqua, Companion, Poultry, and Ruminants. The Aqua is further studied across Aeromonas, Streptococcosis, and Vibrio. The Companion is further studied across Canine and Feline. The Canine is further studied across Canine Herpes, Distemper, Kennel Cough, Lyme Disease, Parvovirus, and Rabies Canine. The Feline is further studied across Calicivirus, Coronavirus Feline, Panleukopenia, Rabies Feline, and Rhinotracheitis. The Poultry is further studied across Avian Influenza, Infectious Bronchitis, Marek's Disease, Newcastle Disease, and Salmonella. The Ruminants is further studied across Coronavirus Ruminants, E. Coli, Foot & mouth disease (FMD), Lumpy skin, and Rotavirus.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Livestock Population
      • 5.1.1.2. Rising Animal Husbandry along with Commercialization of Animal Products
      • 5.1.1.3. Increasing Incidences of Zoonotic Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Supply End Costs are Relatively High, with Poorer Capital Returns than Human Vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Shift from Live Attenuated Vaccines to DNA Vaccines
      • 5.1.3.2. Continuous Technological Advancements in Vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse Impacts of Vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Animal Vaccines Market, by Product

  • 6.1. Introduction
  • 6.2. Attenuated Live Vaccines
  • 6.3. DNA Vaccines
  • 6.4. Inactivated Vaccines
  • 6.5. Recombinant Vaccines
  • 6.6. Subunit Vaccines

7. Animal Vaccines Market, by Animal Type

  • 7.1. Introduction
  • 7.2. Aqua
    • 7.2.1. Aeromonas
    • 7.2.2. Streptococcosis
    • 7.2.3. Vibrio
  • 7.3. Companion
    • 7.3.1. Canine
      • 7.3.1.1. Canine Herpes
      • 7.3.1.2. Distemper
      • 7.3.1.3. Kennel Cough
      • 7.3.1.4. Lyme Disease
      • 7.3.1.5. Parvovirus
      • 7.3.1.6. Rabies Canine
    • 7.3.2. Feline
      • 7.3.2.1. Calicivirus
      • 7.3.2.2. Coronavirus Feline
      • 7.3.2.3. Panleukopenia
      • 7.3.2.4. Rabies Feline
      • 7.3.2.5. Rhinotracheitis
  • 7.4. Poultry
    • 7.4.1. Avian Influenza
    • 7.4.2. Infectious Bronchitis
    • 7.4.3. Marek's Disease
    • 7.4.4. Newcastle Disease
    • 7.4.5. Salmonella
  • 7.5. Ruminants
    • 7.5.1. Coronavirus Ruminants
    • 7.5.2. E. Coli
    • 7.5.3. Foot & mouth disease (FMD)
    • 7.5.4. Lumpy skin
    • 7.5.5. Rotavirus

8. Americas Animal Vaccines Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Animal Vaccines Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Animal Vaccines Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anicon Labor GmbH by SAN Group
  • 2. Biogenesis Bago S.A.
  • 3. Boehringer Ingelheim International GmbH
  • 4. Brilliant Bio Pharma Private limited
  • 5. Ceva Sante Animale
  • 6. China Animal Husbandry Industry Co., Ltd.
  • 7. Dalan Animal Health.
  • 8. Eli Lilly and Company
  • 9. Endovac Animal Health, LLC
  • 10. Heska Corporation
  • 11. Hester Biosciences Limited
  • 12. HIPRA, S.A.
  • 13. Indian Immunologicals Limited
  • 14. Merck KGaA
  • 15. Neogen Corporation
  • 16. Pfizer Inc.
  • 17. Phibro Animal Health Corporation
  • 18. Sanofi S.A.
  • 19. Torigen Pharmaceuticals Inc.
  • 20. Vaxxinova GmbH
  • 21. VEROVACCiNES GmbH
  • 22. Vetigenics
  • 23. Vetoquinol SA
  • 24. Virbac, Inc.
  • 25. Zoetis Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦